ESCITALOPRAM OXALATE - Generic Drug Details

What are the generic drug sources for escitalopram oxalate and what is the scope of freedom to operate?

Escitalopram oxalate is the generic ingredient in three branded drugs marketed by Almatica, Rising, Amneal Pharms, Antrim Pharms Llc, Aurobindo Pharma Ltd, Chartwell Molecular, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Sun Pharma Canada, Abbvie, Accord Hlthcare, Aiping Pharm Inc, Ascent Pharms Inc, Chartwell Rx, Graviti Pharms, Hikma Pharms, Invagen Pharms, Jubilant Cadista, Novitium Pharma, Prinston Inc, Teva Pharms Usa, Torrent Pharms Ltd, and Zydus Lifesciences, and is included in twenty-seven NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-six drug master file entries for escitalopram oxalate. Forty-six suppliers are listed for this compound. There are six tentative approvals for this compound.

Summary for ESCITALOPRAM OXALATE

US Patents:	0
Tradenames:	3
Applicants:	23
NDAs:	27
Drug Master File Entries:	26
Finished Product Suppliers / Packagers:	46
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	25
Drug Prices:	Drug price trends for ESCITALOPRAM OXALATE
Drug Sales Revenues:	Drug sales revenues for ESCITALOPRAM OXALATE
What excipients (inactive ingredients) are in ESCITALOPRAM OXALATE?	ESCITALOPRAM OXALATE excipients list
DailyMed Link:	ESCITALOPRAM OXALATE at DailyMed

See drug prices for ESCITALOPRAM OXALATE

See drug sales revenues for ESCITALOPRAM OXALATE

Recent Clinical Trials for ESCITALOPRAM OXALATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
West China Hospital	NA
The First Affiliated Hospital, Zhejiang University	NA
Gang Wang	NA

See all ESCITALOPRAM OXALATE clinical trials

Generic filers with tentative approvals for ESCITALOPRAM OXALATE

Applicant	Application No.	Strength	Dosage Form
		20MG	TABLET; ORAL
		10MG	TABLET; ORAL
		5MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ESCITALOPRAM OXALATE

Drug Class	Serotonin Reuptake Inhibitor
Mechanism of Action	Serotonin Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ESCITALOPRAM OXALATE

N06AB	Selective serotonin reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

N06AB	Selective serotonin reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for ESCITALOPRAM OXALATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LEXAPRO	Capsules	escitalopram oxalate	5 mg	021323	1	2005-08-17
LEXAPRO	Capsules	escitalopram oxalate	10 mg and 20 mg	021323	1	2005-03-30

US Patents and Regulatory Information for ESCITALOPRAM OXALATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Macleods Pharms Ltd	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	202210-003	Sep 11, 2012	AB	RX	No	No
Amneal Pharms	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	205619-003	May 17, 2017	AB	RX	No	No
Zydus Lifesciences	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	077734-001	Sep 11, 2012	AB	RX	No	No
Novitium Pharma	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	077550-003	May 14, 2015		DISCN	No	No
Aiping Pharm Inc	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	077512-002	Sep 12, 2012		DISCN	No	No
Jubilant Cadista	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	202280-001	Sep 12, 2012	AB	RX	No	No

Expired US Patents for ESCITALOPRAM OXALATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	LEXAPRO	escitalopram oxalate	SOLUTION;ORAL	021365-001	Nov 27, 2002	RE34712*PED
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-003	Aug 14, 2002	RE34712*PED
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-002	Aug 14, 2002	7,420,069*PED
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-003	Aug 14, 2002	7,420,069*PED
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-003	Aug 14, 2002	6,916,941*PED
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-001	Aug 14, 2002	6,916,941*PED

Market Dynamics and Financial Trajectory for Escitalopram Oxalate

Last updated: March 5, 2026

What Is the Current Market Size and Growth Rate for Escitalopram Oxalate?

Escitalopram oxalate, marketed under brand names such as Lexapro, is a selective serotonin reuptake inhibitor (SSRI) prescribed primarily for depression and generalized anxiety disorder. The global antidepressant market was valued at approximately $16.9 billion in 2022 and is expected to reach $24.4 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.9%. Escitalopram accounts for roughly 35-40% of this segment, estimated at $5.9 billion in 2022, with projected revenues exceeding $8.4 billion by 2030.

Market segmentation

Region	2022 Market Share	Projected 2030 Market Share	Key Drivers
North America	45%	45%	High prevalence of depression
Europe	25%	25%	Increasing mental health awareness
Asia-Pacific	20%	20%	Growing healthcare access
Rest of World	10%	10%	Expansion of healthcare coverage

How Do Patent Expirations Affect Market Dynamics?

The original patent for Lexapro expired in 2012 for the core molecule, allowing generic versions to enter the market. Generic escitalopram accounts for over 80% of prescriptions in the U.S. today, significantly reducing brand-name sales.

Generic competition led to a price decline of approximately 60% between 2012 and 2015. Despite this, branded formulations retain revenue through differentiation strategies, such as marketing and formulations with extended-release properties.

What Are the Revenue Trends for Key Pharma Players?

Company	Market Share (2022)	Key Products	Revenue (2022)	Estimated 2025 Revenue
Lundbeck	20%	Cipralex (Lexapro in EU)	$350 million	$500 million
Teva	15%	generic escitalopram	$1.5 billion	$1.8 billion
Allergan (AbbVie)	10%	generic formulations	$700 million	$900 million
Others	55%	various generics	$5.3 billion	$6.3 billion

Revenue is driven by both brand retention in select markets and generic sales. The trend toward bioequivalent formulations fuels generic sales growth.

How Will Competitive and Regulatory Factors Shape the Market?

Generic erosion persists, but branded sales maintain presence via strategic pricing and indications beyond depression, such as obsessive-compulsive disorder.

Regulatory actions in various markets impact pricing and marketing. The U.S. Food and Drug Administration (FDA) approved multiple generics from 2012 onwards, intensifying price competition.

Accelerating approval pathways for biosimilars and specialty formulations present potential pathways for pharma companies seeking market share. Meanwhile, patent litigations remain a barrier for certain formulations, impacting market entry strategies.

What Is the R&D Outlook and Innovation Pipeline?

Research into extended-release formulations aims to improve patient adherence. Advances in digital health integrations, such as drug delivery monitoring, are under clinical evaluation.

Pipeline candidates include combination therapies targeting treatment-resistant depression and formulations optimized for higher bioavailability.

What Are the Key Challenges and Opportunities?

Challenges:

• High generic market penetration limits profitability of branded drugs.
• Price erosion affects revenue growth.
• Regulatory environment remains competitive, with Active Pharmaceutical Ingredient (API) sourcing issues.

Opportunities:

• Developing novel formulations with improved efficacy.
• Expanding indications into other mental health conditions.
• Differentiating through digital health integrations.

Key Takeaways

• The global escitalopram market was valued at approximately $5.9 billion in 2022, with projections exceeding $8.4 billion by 2030.
• Patent expirations significantly suppressed branded sales post-2012, increasing generic market share.
• Leading companies like Lundbeck and Teva dominate the market, with revenue shifts driven by generic competition.
• Innovation in formulations and indications offers growth avenues, despite pricing pressures.
• Regulatory and patent environments remain pivotal in shaping market dynamics and entry strategies.

5 FAQs

1. When did the patent for Lexapro expire?
The primary patent for Lexapro (escitalopram) expired in the United States in 2012, leading to widespread generic availability.

2. What percentage of the market is held by generic escitalopram?
Over 80% of prescriptions for escitalopram in the U.S. are filled with generic formulations.

3. Are there advanced formulations of escitalopram in development?
Yes. Extended-release formulations and combination therapies are in clinical trials, aiming to improve adherence and broaden therapeutic indications.

4. How does regional variation influence market size?
North America and Europe dominate the market, accounting for approximately 70–75%. Asia-Pacific represents a rapidly growing segment due to increased healthcare access.

5. What are the main hurdles for branded escitalopram sales?
Patent expiry, aggressive generic pricing, and regulatory approvals of new generics challenge branded sales continuity.

References

[1] Grandview Research. (2023). Antidepressant Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). National Prescription Audit.
[3] U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).